`
`Year
`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`Years 1–6
`Total
`
`1st Decile
`
`2nd Decile
`
`Mean
`
`Toviaz U.S.
`
`Toviaz Worldwide
`
`[A]
`300$
`
`
`550$
`
`800$
`
`1,100$
`
`1,450$
`
`1,730$
`
`2,000$
`
`2,200$
`
`2,390$
`
`2,510$
`
`2,540$
`
`2,590$
`
`2,590$
`
`2,570$
`
`1,990$
`
`1,490$
`
`1,190$
`
`950$
`
`770$
`
`620$
`
`5,930$
`$
`32,330
`
`[A]
`150$
`
`
`280$
`
`390$
`
`500$
`
`630$
`
`740$
`
`840$
`
`900$
`
`950$
`
`890$
`
`790$
`
`780$
`
`660$
`
`560$
`
`440$
`
`320$
`
`250$
`
`200$
`
`160$
`
`120$
`
`2,690$
`
`10,550$
`
`[A]
`90$
`
`160$
`
`
`210$
`
`270$
`
`320$
`
`370$
`
`420$
`
`430$
`
`450$
`
`460$
`
`450$
`
`440$
`
`420$
`
`390$
`
`310$
`
`230$
`
`180$
`
`150$
`
`110$
`
`90$
`
`1,420$
`
`5,950$
`
`[B]
`9$
`
`43$
`
`
`72$
`
`86$
`
`89$
`
`97$
`
`[B]
`47$
`
`108$
`
`
`143$
`
`155$
`
`174$
`
`209$
`
`396$
`
`
`396$
`
`838$
`
`
`838$
`
`Notes and sources:
`Figures are in millions of 2000 $U.S.
`[A] Grabowski, Henry, John Vernon, and Joseph A. DiMasi (2002), “Returns on Research and Development for 1990s New Drug Introductions,"
`Pharmacoeconomics 20(3): 11–29, at 17.
`Sales are estimated and rounded to the nearest $10 million based on Figure 2.
`[B] Exhibit 1036. Sales are converted to 2000 $U.S. based on the CPI per Exhibit 1049.
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1042 - Page 1